---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019795"
form_type: "8-K"
ticker: "BPTH"
cik: "0001133818"
company_name: "BIO-PATH HOLDINGS, INC."
filed_at: "2023-12-14T23:59:59+00:00"
generated_at: "2026-06-07T12:31:41.610148+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bio-Path completes first dose cohort of BP1002 Phase 1/1b trial in AML; no dose-limiting toxicities

## Summary
- First cohort (20 mg/m2) completed with no dose-limiting toxicities in 3 evaluable refractory/relapsed AML patients.
- BP1002 uses RNAi to limit Bcl-2 protein production, offering potential treatment for venetoclax-resistant patients.
- Treatment cycle: two doses per week for 4 weeks (8 doses over 28 days).
- Phase 1b portion will assess BP1002 in combination with decitabine after monotherapy cohorts.
- National PI is Dr. Gail Roboz, director of Clinical and Translational Leukemia Program at Weill Cornell.

## SEC filing metadata
- accession: 0001558370-23-019795
- form_type: 8-K
- ticker: BPTH
- cik: 0001133818
- company_name: BIO-PATH HOLDINGS, INC.
- filed_at: 2023-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/0001558370-23-019795-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1133818/000155837023019795/bpth-20231214x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019795
- JSON: https://secwatch.observer/filing/0001558370-23-019795.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019795.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.